Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood blood.2024024582.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2023) 142 (Supplement 1): 2101.

https://doi.org/10.1182/blood-2023-173970

Published: 2023

Journal Articles

Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)

Tulio E. Rodriguez, MD, Parameswaran Hari, MD, MS, Patrick J Stiff, MD, Xiaobo Zhong, MS, Danielle Sterrenberg, MD, David H. Vesole, MD, PhD

Blood (2013) 122 (21): 3357.

https://doi.org/10.1182/blood.V122.21.3357.3357

Published: 2013

Journal Articles

Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes

Daniel J. Weisdorf, MD, Mary Eapen, MBBS, MS, Annalisa Ruggeri, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Claudio Brunstein, MD, Celalettin Ustun, Vanderson Rocha, MD, Eliane Gluckman, MD

Blood (2013) 122 (21): 302.

https://doi.org/10.1182/blood.V122.21.302.302

Published: 2013

Journal Articles

Multiple Myeloma (MM) In Older (>70 year) Patients - Similar Benefit From Autologous Hematopoietic Cell Transplantation (AHCT) Compared With Younger Patients

Manish Sharma, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Cristina J. Gasparetto, MD, Amrita Y. Krishnan, MD, Sagar Lonial, M.D., Parameswaran Hari, MD, MS

Blood (2013) 122 (21): 416.

https://doi.org/10.1182/blood.V122.21.416.416

Published: 2013

Journal Articles

Transplantation Of Peripheral Blood Progenitor Cells (PBPC) As Compared To Bone Marrow (BM) From Unrelated Related Donors For Hematologic Cancers Using Fludarabine-Alkylating Agent Based Reduced Intensity Conditioning Regimens

Mary Eapen, MBBS, MS, Brent R. Logan, PhD, Mary M. Horowitz, MD, MS, Xiaobo Zhong, MS, Miguel Angel Perales, MD, Stephanie J. Lee, MD, MPH, Vanderson Rocha, MD, Robert J. Soiffer, MD, Daniel J. Weisdorf, MD, Richard E Champlin, MD

Blood (2013) 122 (21): 550.

https://doi.org/10.1182/blood.V122.21.550.550

Published: 2013

Journal Articles

Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)

Anuj Mahindra, Ayman A Saad, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Angela Dispenzieri, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Marcelo C Pasquini, MD, MS, Parameswaran Hari, MBBS, MD, MRCP

Blood (2012) 120 (21): 4217.

https://doi.org/10.1182/blood.V120.21.4217.4217

Published: 2012

Journal Articles

Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Girindra Raval, Anuj Mahindra, MD, Xiaobo Zhong, MS, Ruta Brazauskas, PhD, Robert Peter Gale, MD, PhD, DSc, FACP, Nancy Brandenburg, PhD, Sagar Lonial, MD, Amrita Krishnan, MD, Angela Dispenzieri, MD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2012) 120 (21): 591.

https://doi.org/10.1182/blood.V120.21.591.591

Published: 2012

Journal Articles

Trends in Utilization and Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) in the Upfront Management of Patients with Multiple Myeloma: A Cibmtr Analysis

Luciano J. Costa, MD, PhD, Xiaobo Zhong, MS, Mei-Jie Zhang, PhD, Sagar Lonial, MD, Amrita Krishnan, MD, Angela Dispenzieri, MD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2012) 120 (21): 596.

https://doi.org/10.1182/blood.V120.21.596.596

Published: 2012

Journal Articles

Pre-Transplant Salvage Therapy Prior to Autologous Transplant (AHCT) in Patients Not Responding to Initial Induction for Multiple Myeloma (MM)

Ravi Vij, MBBS, Xiaobo Zhong, MS, Mei-Jie Zhang, PhD, Sagar Lonial, MD, Angela Dispenzieri, MD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2012) 120 (21): 597.

https://doi.org/10.1182/blood.V120.21.597.597

Published: 2012

Journal Articles

Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) – a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)

Ayman A Saad, MD, David H. Vesole, MD, PhD, Jennifer Le-Rademacher, PhD, Xiaobo Zhong, MS, Angela Dispenzieri, MD, Sagar Lonial, MD, Gustavo A. Milone, MD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 504.

https://doi.org/10.1182/blood.V118.21.504.504

Published: 2011

Journal Articles

Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)

Cesar O. Freytes, MD, David H. Vesole, MD, PhD, Xiaobo Zhong, MS, Jennifer Le-Rademacher, PhD, Angela Dispenzieri, MD, Sagar Lonial, MD, Gustavo Milone, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 824.

https://doi.org/10.1182/blood.V118.21.824.824

Published: 2011

NARROW

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)

Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes

Multiple Myeloma (MM) In Older (>70 year) Patients - Similar Benefit From Autologous Hematopoietic Cell Transplantation (AHCT) Compared With Younger Patients

Transplantation Of Peripheral Blood Progenitor Cells (PBPC) As Compared To Bone Marrow (BM) From Unrelated Related Donors For Hematologic Cancers Using Fludarabine-Alkylating Agent Based Reduced Intensity Conditioning Regimens

Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)

Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Trends in Utilization and Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) in the Upfront Management of Patients with Multiple Myeloma: A Cibmtr Analysis

Pre-Transplant Salvage Therapy Prior to Autologous Transplant (AHCT) in Patients Not Responding to Initial Induction for Multiple Myeloma (MM)

Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) – a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)

Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only